Computational Investigation of Phytochemicals Targeting AKT1 for Major Depressive Disorder: A Molecular Docking and ADMET Study

Year : 2025 | Volume : 14 | Issue : 02 | Page :
    By

    Chakresh Kumar Jain,

  • Abhimanyu Chauhan,

  1. Associate Professor, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India
  2. Student, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India

Abstract

Major depressive disorder (MDD) is a prevalent neuropsychiatric condition affecting approximately 280 million individuals worldwide, with women exhibiting a 50% higher likelihood of diagnosis than men. Despite significant advancements in treatment, MDD remains a chronic and relapsing disorder, necessitating the exploration of novel therapeutic interventions. This study focuses on the AKT1 gene, a key player in neuropsychiatric disorders, and investigates its interactions with natural phytochemicals as potential alternatives to conventional antidepressants. Molecular docking analysis was conducted using the AKT1 protein structure (PDB ID: 3O96) to evaluate the binding affinities of FDA-approved antidepressants and selected phytochemicals derived from Ayurvedic medicinal plants. Active site prediction using CASTpFold identified a binding pocket with a surface area of 1665.060 Ų and a volume of 1365.991 ų. Docking studies revealed that Cannflavin A and Betulinic Acid exhibited superior binding affinities (-10.6 and -10.3 kcal/mol, respectively) compared to Paroxetine (-10.2 kcal/mol) and Sertraline (-9.7 kcal/mol). Interaction analysis highlighted stronger hydrogen bonding, hydrophobic interactions, and van der Waals forces in Cannflavin A compared to Paroxetine, suggesting enhanced binding stability. Furthermore, ADMET analysis confirmed favorable pharmacokinetic properties for Cannflavin A, reinforcing its potential as a natural therapeutic agent for MDD. These findings underscore the promise of phytochemicals in modulating AKT1 activity and provide a foundation for future preclinical and clinical investigations into their antidepressant potential

Keywords: MDD, Docking , AKT1, Cannflavin A, Betulinic Acid

[This article belongs to Research and Reviews : Journal of Computational Biology ]

How to cite this article:
Chakresh Kumar Jain, Abhimanyu Chauhan. Computational Investigation of Phytochemicals Targeting AKT1 for Major Depressive Disorder: A Molecular Docking and ADMET Study. Research and Reviews : Journal of Computational Biology. 2025; 14(02):-.
How to cite this URL:
Chakresh Kumar Jain, Abhimanyu Chauhan. Computational Investigation of Phytochemicals Targeting AKT1 for Major Depressive Disorder: A Molecular Docking and ADMET Study. Research and Reviews : Journal of Computational Biology. 2025; 14(02):-. Available from: https://journals.stmjournals.com/rrjocb/article=2025/view=202552


References

[1] J. Q. Wang and L. Mao, “The ERK Pathway: Molecular Mechanisms and Treatment of Depression,” Mol Neurobiol, vol. 56, no. 9, pp. 6197–6205, Sep. 2019, doi: 10.1007/s12035-019-1524-3.
[2] “Depressive disorder (depression).” Accessed: Mar. 18, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/depression
[3] L. Cui et al., “Major depressive disorder: hypothesis, mechanism, prevention and treatment,” Signal Transduct Target Ther, vol. 9, no. 1, p. 30, Feb. 2024, doi: 10.1038/s41392-024-01738-y.
[4] J. Ormel, A. J. Oldehinkel, W. A. Nolen, and W. Vollebergh, “Psychosocial Disability Before, During, and After a Major DepressiveEpisode,” Arch Gen Psychiatry, vol. 61, no. 4, p. 387, Apr. 2004, doi: 10.1001/archpsyc.61.4.387.
[5] Z. Lu et al., “Exploring the pathogenesis of depression and potential antidepressants through the integration of reverse network pharmacology, molecular docking, and molecular dynamics.,” Medicine, vol. 102, no. 44, p. e35793, Nov. 2023, doi: 10.1097/MD.0000000000035793.
[6] C. Yang et al., “Association between AKT1 gene polymorphisms and depressive symptoms in the Chinese Han population with major depressive disorder.,” Neural Regen Res, vol. 7, no. 3, pp. 235–9, Jan. 2012, doi: 10.3969/j.issn.1673-5374.2012.03.014.
[7] T. Del’Guidice and J.-M. Beaulieu, “Un rôle pour la voie de signalisation Akt/GSK3 dans l’action des médicaments psychotropes et les maladies mentales,” médecine/sciences, vol. 26, no. 6–7, pp. 647–651, Jun. 2010, doi: 10.1051/medsci/2010266-7647.
[8] Abhimanyu and C. K. Jain, “Computational Interaction Study of Immunomodulatory Plant Derivatives Against SARS-Cov-2 Mpro Target,” in Phytochemical Genomics: Plant Metabolomics and Medicinal Plant Genomics, M. K. Swamy and A. Kumar, Eds., Singapore: Springer Nature Singapore, 2022, pp. 681–698. doi: 10.1007/978-981-19-5779-6_29.
[9] R. Chandre, B. N. Upadhyay, and K. H. H. V. S. S. N. Murthy, “Clinical evaluation of Kushmanda Ghrita in the management of depressive illness.,” Ayu, vol. 32, no. 2, pp. 230–3, Apr. 2011, doi: 10.4103/0974-8520.92592.
[10] B. Ye, W. Tian, B. Wang, and J. Liang, “CASTpFold: Computed Atlas of Surface Topography of the universe of protein Folds,” Nucleic Acids Res, vol. 52, no. W1, pp. W194–W199, Jul. 2024, doi: 10.1093/nar/gkae415.
[11] S. Kim et al., “PubChem 2023 update,” Nucleic Acids Res, vol. 51, no. D1, pp. D1373–D1380, Jan. 2023, doi: 10.1093/nar/gkac956.
[12] J. Eberhardt, D. Santos-Martins, A. F. Tillack, and S. Forli, “AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings,” J Chem Inf Model, vol. 61, no. 8, pp. 3891–3898, Aug. 2021, doi: 10.1021/acs.jcim.1c00203.
[13] C. A. Lipinski, “Lead- and drug-like compounds: the rule-of-five revolution,” Drug Discov Today Technol, vol. 1, no. 4, pp. 337–341, Dec. 2004, doi: 10.1016/j.ddtec.2004.11.007.
[14] F. Cheng et al., “admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties,” J Chem Inf Model, vol. 52, no. 11, pp. 3099–3105, Nov. 2012, doi: 10.1021/ci300367a.
[15] A. Daina, O. Michielin, and V. Zoete, “SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Sci Rep, vol. 7, no. 1, p. 42717, Mar. 2017, doi: 10.1038/srep42717.

Regular Issue Subscription Original Research
Volume 14
Issue 02
Received 18/02/2025
Accepted 25/02/2025
Published 03/03/2025
Publication Time 13 Days
200


My IP

PlumX Metrics